Background Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with
a poor prognosis. Recently, pirfenidone was reported to slow the rate of decline in vital …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective
therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial …

Objective Long-term effects of pirfenidone have been poorly understood to date. This study
investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic …

Background A phase III clinical trial of pirfenidone in patients with idiopathic pulmonary
fibrosis (IPF) in Japan has revealed that pirfenidone attenuated the decline in vital capacity …

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although
the precise cause of the disease is still unknown, recent studies have shown that the …

Background Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five
randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of …

Data from controlled clinical studies in patients with more advanced idiopathic pulmonary
fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with a
median survival of 2–5 years and limited treatment options. In 2008, pirfenidone became the …

Background: Although phase 3 trials showed significant efficacy and acceptable safety
profiles for pirfenidone in mild-to-moderate idiopathic pulmonary fibrosis (IPF), data on …

Background A phase III trial in Japan showed that pirfenidone is effective for idiopathic
pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we …